This article has been updated to clarify the enrollment challenges with the InVite Study.
FDA Rejects Avastin as Breast Cancer Drug; Genentech to Conduct New Trial to ID Best Responders
Originally published Nov. 18. By Turna Ray
'Middle Ground' Avastin Proposal Could Maintain Access for Molecularly Defined Breast Cancer Patients
Originally published Aug. 16. By Turna Ray
Mar 2, 2011